NCTN Breast Cancer Trials Portfolio (Open as of 4/15/2024)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Neoadjuvant

EA1211 (DIRECT)
HER2+
Stage IIa-IIIc

S2212 (SCARLET)
TNBC
T2-4/N0/M0, or T1-3/N1-2/M0

S2206
HR+/HER2-
Stage II or III

Post-Neoadjuvant

S1706
Any HR/HER2 status
Inflammatory; No mets

A011801 (COMPASS-RD)
HER2+
T1-4, N0-3
Any HR-; If HR+, node+

A012103 (OptimICE-PCR)
TNBC
Early-Stage, pCR post pre-op chemo + pembrolizumab

NRG-BR008 (HERO)
HER2+
Low risk, N0M0

Adjuvant

CCTG MA.39
HR+/HER2-
Low risk; Node positive

NRG-BR007 (DEBRA)
HR+/HER2-
pT1(<=2cm) pN0M0

NRG-BR009 (OFSET)
HR+/HER2-
pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients

Metastatic

S2007
HER2-
Brain metastases

Sub-study: EAY191-N2
HR+/HER2-
NF1 Nonsense/Frameshift mutation

EAY191 (ComboMATCH)

Sub-study: EAY191-A3
(RAS-mutant)

Sub-study: EAY191-E4
(Prior Taxane-treated)

Sub-study: EAY191-E5
(KRAS G12C mutation)

Legend by Subtype Status

- White = Any HR/HER2 status
- Blue = HER2- (Any HR status)
- Green = TNBC
- Orange = HER2+ (Any HR status)
- Purple = HR+ and HER2-
- Yellow = HR+ (Any HER2 status)
- Pink = Cross-disease trial

NCTN Breast Cancer Trials (Open as of 4/15/2024)

Protocol Number	Phase	Protocol Title
A011801	III	The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
A012103	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
CCTG MA.39	III	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
EA1211	II	Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial
NRG-BR007	III	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer (DEBRA)
NRG-BR008	III	A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET)
S1706	II	A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
S2007	II	A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
S2206	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
S2212	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-A3	II	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
EAY191-E4	II	Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial
EAY191-E5	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
EAY191-N2	II	Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find-a-study/